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GUIDING PRINCIPLES FOR THE DEVELOPMENT OF THE CGIAR 
CENTRES’ POLICIES TO ADDRESS THE POSSIBILITY OF 
UNINTENTIONAL PRESENCE OF TRANSGENES IN EX SITU 
COLLECTIONS 
Background 
1. In the management of germplasm, the CGIAR Centres embrace the following 
overarching principles: ethics, transparency, accountability, risk analysis and 
quality control. 
2. The purpose of genebanks is to collect, conserve and make genetic resources 
available. The maintenance of the genetic identity of the accessions is an 
overriding objective of genebanks. The Centres take proactive steps that aim 
to prevent the unintentional introgression of exotic genes, including 
transgenes, not already present into samples conserved in their genebanks.  
Proper germplasm management procedures and genebank practices and 
protocols to ensure quality and integrity of accessions must be followed. 
3. Transgenes and conventional genes are subject to the same underlying 
biological processes of mutation, geneflow, introgression, recombination and 
natural selection. Therefore, best practices for preventing introgression of 
conventional genes provide an appropriate basis for preventing introgression 
of transgenes. 
4. Germplasm management procedures and practices should conform to best 
practices. Best practices and appropriate technologies vary with the crop, 
influenced, for example, by its breeding system, pollination system, and 
whether it is an annual/perennial. These best practices include procedures and 
practices that aim to prevent the transfer of genes from sources other than the 
accession in question. Routes for transfer by other sources include admixture 
of seeds and pollination. 
5. It is recognized that available technical means do not permit the complete 
exclusion of unintentional presence of exotic genes, including transgenes, in 
genebank accessions. It is also recognized that available testing techniques do 
not provide an absolute guarantee, without testing every single seed or plant 
that any given accession is free of transgenes. However, best practices in 
genebanks will achieve a high degree of statistical probability that an 
accession does not include unintentionally present transgenes. 
 
Guiding Principles 
6. The Centres should take proactive steps to determine the risk of the 
unintentional presence of exotic genes, including transgenes, in their ex situ 
collections. 
7. The Centres should develop, document and communicate crop-specific 
guidelines for best gene bank management practices. These guidelines should 
include crop-specific risk analysis procedures (i.e., risk assessment, 
management, and communication) addressing critical control points.    
8. The major genebank operations that need to be evaluated are collecting, 
acquisition, regeneration, characterization, delivery, conservation, testing 
health and viability, evaluation and documentation (genebanks are most open 
to unintentional introduction of transgenes at the collecting and acquisition 
stage, because germplasm may have been exposed to geneflow outside the 
control of the genebank). 
The guidelines must aim to minimize geneflow at these stages, for transgenes 
and for conventional genes.    
9. As part of their risk analysis, when collecting or acquiring new accessions by 
other means, Centres should consider the following regarding testing: 
a. whether transgenic events (commercial and research) in the relevant 
taxa are likely to be present in the area of collecting or acquisition; 
b. the distance between the collecting site and areas where transgenic 
events (commercial and research) are situated; or    
c. whether germplasm providers can provide adequate documentation of 
their germplasm management practices with respect to the material in 
question.   
10. With respect to existing accessions, Centres' testing procedures should be 
guided by the following criteria:    
a. No testing would be required when: 
i. there are no transgenic events (commercial or research) in the 
relevant taxa at the present time; 
ii. there were no transgenic events (commercial or research) in the 
relevant taxa at the time of acquisition (e.g., maize prior to 
1996); 
iii. it is determined that, unless there are other factors, there is no 
presence of transgenic events within a distance that would 
allow for introgression; or  
iv. there are transgenic events (commercial or research) present, 
however, proper management practices have been followed and 
documented in the management of the accession,  
 
b. Tests should be undertaken when there are transgenic events 
(commercial or research) present and good management practices 
cannot be demonstrated.    
c. Once an accession has been determined to either not require testing or 
has tested negative, the Centre will follow best practice regeneration 
and maintenance procedures to maintain the genetic integrity, as for 
all accessions.    
11. If and when transgenes are detected in an accession, in following best practice 
management procedures, the Centres will take appropriate steps to prevent 
introgression of those transgenes to other accessions.    
12. The Centres should establish and maintain a database on the global status of 
GM research and development for the crops within their collections in order 
to facilitate risk analysis. The database should be posted on a publicly 
accessible website.    
13. The Centre should bear the costs of the procedures, including tests when 
necessary, set out above. Requests for additional assurances above those 
established by the Centre should be met through additional funds on a case-
by-case basis from outside sources.    
14. Upon request by the recipients of materials, the Centre will provide 
information describing procedures and tests that the Centre has followed for 
the accession concerned. 
 
15. All data resulting from any testing should be properly documented and made 
publicly available as soon as it is considered scientifically reliable (e.g., by 
posting on the Centre's web site). All procedures and supporting information 
should be presented at the same time. The Centre will also inform the relevant 
authority of the country of collecting or acquisition of the material in question 
when transgenes are found; the Centre will also inform the relevant authority 
of the country in which the Centre is located.    
